<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82275">
  <stage>Registered</stage>
  <submitdate>11/09/2007</submitdate>
  <approvaldate>18/09/2007</approvaldate>
  <actrnumber>ACTRN12607000467437</actrnumber>
  <trial_identification>
    <studytitle>Reinfection Potential of Helicobacter pylori Pilot Study</studytitle>
    <scientifictitle>Reinfection Potential of Helicobacter pylori Pilot Study</scientifictitle>
    <utrn />
    <trialacronym>None</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>To test the hypothesis that persons can be reinfected with their own strain of H.pylori on multiple occasions</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Healthy participants will be screened for H.pylori infection using Carbon 14 Urea Breath Test (C14 UBT). If infected they will proceed to gastroscopy followed by treatment with the  oral antibiotics to eradicate the H.pylori infection. The antibiotics used will be "Nexium HP7"
(containing amoxycillin 1 G twice daily; clarithromycin 500 mg twice daily; esomeprazole 20mg twice daily) for 7 days and "Tinidazole" 500mg twice daily on days 5-7 of the antibiotic treatments. There will be 3 gastroscopies and antibiotic treatments and 2 cycles of reinfections  done by drinking cultures of their own strain of h.pylori bacteria in a one off drink The reinfection will be done at least 28 days after treatment with antibiotics. The interventions, treatments and reinfections will be done in approximately 3-4 monthly cycles. There is no wash out period.</interventions>
    <comparator>uncontrolled group. All participants will undergo all treatments and interventions</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Test for positive reinfection using participants' own strain of bacteria. Infection confirmed with "C14 UBT" 14- 30 days after reinfection. Only one "C14 UBT" will be done in that time period.</outcome>
      <timepoint>14-30 days after reinfection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Healthy men /women
2.Aged 18-65 inclusive
3.No known allergy to principal medication/antibiotics used to treat H.pylori in this study
No known intolerances or allergy to 2nd and 3rd line medication/antibiotics used to treat H.pylori, including macrolites, tetracycline, fluoroquinolones, furazolidone, colloidal bismuth subcitrate
4. Living in Australia for duration of trial (approximately 12-18 months)
5. Speaks English
6. Minimum high school education
7. Priority given to volunteers who own a mobile phone
8. Provide informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or breast feeding women; women who are less than 2 years postmenopausal; or women of child bearing potential not using adequate contraception for the duration of the study (adequate ccontraception is the use of oral contraceptives, contraceptive injections, intra-uterine device, contraceptive patches, or the use of a double barrier contraception method (e.g. use of condom and spermicidal cream simultaneously) Women of child bearing potential can safely take the 1st screening "PYtest C14 UBT" at visit 1, but will be required to have a negative serum Beta Human Chorionic Gonadatrophin pregnancy test before continuing in the study
2. History of recurrent infections requiring treatment with antibiotics
3. Current or probable requirement to use any of the following medications: anticoagulants, aspirin, antibiotics, proton pump inhibitors or regular use of non steroidal anti-inflammatory drugs( more than twice weekly)
4. Current enrolment in another clinical trial involving a medication or device
5. Living with or having daily contact with children aged 12 years or younger at home, school, day care or equivalent facilities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>18/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6009</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ondek Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Locked Bag 15
Subiaco WA 6904</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ondek Pty Ltd</fundingname>
      <fundingaddress>Locked Bag 15
Subiaco WA 6904</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to test the scientific theory that persons can be reinfected with H.pylori on multiple occasions. If so, then a genetically modified H.pylori strain may be the ideal delivery system for live oral vaccines.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>E Block
Hospital Avenue
Nedlands WA 6009</ethicaddress>
      <ethicapprovaldate>21/08/2007</ethicapprovaldate>
      <hrec>2007-045</hrec>
      <ethicsubmitdate>1/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry J Marshall</name>
      <address>Sir Charles Gairdner Hospital
Department of Gastroenterology, G75
Hospital Avenue
Nedlands WA 6009</address>
      <phone>08 9346 4815</phone>
      <fax>08 9346 4816</fax>
      <email>admin@hpylori.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ros Stott</name>
      <address>Sir Charles Gairdner Hospital
Department of Gastroenterology, G75
Hospital Avenue
Nedlands WA 6009</address>
      <phone>08 9346 4036</phone>
      <fax>08 9346 3207</fax>
      <email>rosalind.stott@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ros Stott</name>
      <address>Sir Charles Gairdner Hospital
Department of Gastroenterology, G75
Hospital Avenue
Nedlands WA 6009</address>
      <phone>08 9346 4036</phone>
      <fax>08 9346 3207</fax>
      <email>rosalind.stott@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>